Abstract
Intravenous mineralocorticoid receptor antagonists (MRAs) have been used in some centers for decades to reduce the risk of hypokalemia and boost diuresis in acutely decompensated heart failure (ADHF). We report the well-tolerated use of intravenous MRAs as a rescue procedure in 3 patients admitted for ADHF with important diuretic resistance. Undertaking trials evaluating the effect of this therapeutic strategy in ADHF could represent a promising avenue.
Keywords:
Cardiac edema; Cardiovascular diseases; Congestive heart failure; Dyspnea; Furosemide; Potassium canrenoate.
MeSH terms
-
Administration, Intravenous
-
Aged
-
Aged, 80 and over
-
Bumetanide / administration & dosage
-
Bumetanide / therapeutic use
-
Canrenoic Acid / administration & dosage
-
Canrenoic Acid / pharmacology*
-
Canrenoic Acid / therapeutic use
-
Creatinine / blood
-
Diuresis / drug effects*
-
Diuretics / administration & dosage
-
Diuretics / therapeutic use
-
Drug Combinations
-
Drug Resistance
-
Furosemide / administration & dosage
-
Furosemide / therapeutic use
-
Heart Failure / drug therapy*
-
Humans
-
Hydrochlorothiazide / administration & dosage
-
Hydrochlorothiazide / therapeutic use
-
Male
-
Mineralocorticoid Receptor Antagonists / administration & dosage
-
Mineralocorticoid Receptor Antagonists / pharmacology*
-
Mineralocorticoid Receptor Antagonists / therapeutic use
-
Potassium / blood
-
Treatment Outcome
Substances
-
Diuretics
-
Drug Combinations
-
Mineralocorticoid Receptor Antagonists
-
Hydrochlorothiazide
-
Bumetanide
-
Furosemide
-
Canrenoic Acid
-
Creatinine
-
Potassium